| Released | Contributor | Author | Title | Pages | Price |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for NRGN | 13 |
$25 |
| 21-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: NEUROGEN CORP | 5 |
$25 |
| 21-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Neurogen Corp | 5 |
$25 |
| 20-Nov-2009 | Pechala's Reports | Lubomir Pechala | NEUROGEN CORP (NRGN=US) 2-weeks forecast | 1 |
$10 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: NEUROGEN -- NRGN | 1 |
$4 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ACUR , AMLN , LCI , MTXX , NRGN , SLXP -- DRUGS | 3 |
$4 |
| 17-Nov-2009 | EconomicInvestor |
N/A
| "The Economy Matters" Report for NRGN: the economy's impact on NRGN's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
1.48% Nasdaq 
Research Reports
